Cancer Immunotherapy with CDK7 Inhibitors

Giulia Petroni; Lorenzo Galluzzi

doi:10.1016/j.trecan.2020.02.005

Cancer Immunotherapy with CDK7 Inhibitors

Trends Cancer. 2020 May;6(5):361-363. doi: 10.1016/j.trecan.2020.02.005. Epub 2020 Feb 28.

Authors

Giulia Petroni¹, Lorenzo Galluzzi²

Affiliations

¹ Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
² Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA; Sandra and Edward Meyer Cancer Center, New York, NY, USA; Caryl and Israel Englander Institute for Precision Medicine, New York, NY, USA; Department of Dermatology, Yale School of Medicine, New Haven, CT, USA; Université de Paris, Paris, France. Electronic address: deadoc80@gmail.com.

PMID: 32348731
DOI: 10.1016/j.trecan.2020.02.005

Abstract

Recent findings demonstrate that pharmacological cyclin-dependent kinase 7 (CDK7) inhibitors can evoke anticancer immunity upon genomic destabilization of neoplastic cells. Besides adding CDK7 to the expanding list of cell cycle proteins that impinge on immune regulation, these results support the value of aggravating genomic instability in cancer cells to enable immunological disease control.

Keywords: PD-1; YKL-5-124; immune checkpoint blockade; micronuclei; small cell lung cancer; type I interferon.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Genomic Instability
Humans
Immunotherapy*
Neoplasms*